Lexeo Therapeutics, Inc. Common Stock (LXEO) Financial Ratios
6 years of historical data (2020–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
1.10
↓-54% vs avg
5yr avg: 2.37
30Y Low1.8·High3.1
ROE
↑
-55.0%
↓+99% vs avg
5yr avg: -7665.1%
30Y Low-85%·High-55%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
LXEO Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Lexeo Therapeutics, Inc. Common Stock currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $396M | $533M | $209M | $358M | — | — | — |
| Enterprise Value | $341M | $478M | $184M | $248M | — | — | — |
| P/E Ratio → | -2.71 | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — |
| P/B Ratio | 1.10 | 2.16 | 1.79 | 3.15 | — | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
LXEO EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
LXEO Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -55.0% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | 100.0% | 100.0% | 100.0% |
| Operating Margin | — | — | — | — | -9252.1% | -3055.9% | -884.9% |
| Net Profit Margin | — | — | — | — | -9063.8% | -3055.0% | -993.8% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -55.0% | -55.0% | -85.4% | -22855.1% | — | — | — |
| ROA | -48.1% | -48.1% | -68.6% | -56.1% | -50.7% | -60.9% | -17.5% |
| ROIC | -57.8% | -57.8% | -166.2% | — | — | — | — |
| ROCE | -58.1% | -58.1% | -85.8% | -66.7% | -57.0% | -64.0% | -16.0% |
LXEO Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $63M exceeds total debt of $8M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.08 | 0.10 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.22 | -0.21 | -0.97 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | -484.25 | -484.25 | -861.37 | -322.87 | -650.40 | — | -31.18 |
Net cash position: cash ($63M) exceeds total debt ($8M)
LXEO Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Lexeo Therapeutics, Inc. Common Stock's current ratio of 11.21x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 7.21x to 11.21x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 11.21 | 11.21 | 5.52 | 7.21 | 5.58 | 18.35 | 42.15 |
| Quick Ratio | 11.21 | 11.21 | 5.52 | 7.21 | 5.58 | 18.35 | 42.15 |
| Cash Ratio | 10.81 | 10.81 | 5.32 | 7.05 | 5.39 | 18.24 | 42.10 |
| Asset Turnover | — | — | — | — | 0.01 | 0.01 | 0.02 |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — |
LXEO Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Lexeo Therapeutics, Inc. Common Stock does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $54M | $32M | $27M | $25M | $25M | $25M |
Peer Comparison
Compare LXEO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 LXEOYou | $396M | -2.7 | — | — | — | — | -55.0% | -57.8% | — |
 RCKT | $378M | -1.7 | — | — | — | — | -60.3% | -62.4% | — |
 KRYS | $10B | 50.2 | 57.4 | 53.6 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 SGMO | $73M | -0.4 | — | — | 80.8% | -273.1% | -2891.8% | -5405.6% | — |
 RARE | $3B | -5.0 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 ACAD | $4B | 9.6 | 26.3 | 36.0 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 PRAX | $9B | -22.5 | — | — | — | — | -45.8% | -65.0% | — |
 ARWR | $12B | -6721.3 | 95.6 | 73.6 | 100.0% | 11.9% | -0.5% | 9.3% | 3.0 |
 NTLA | $2B | -4.1 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 CRSP | $5B | -8.4 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.4 | 63.9% | -4.4% | -33.2% | -11.7% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 6 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
LXEO — Frequently Asked Questions
Quick answers to the most common questions about buying LXEO stock.
What is Lexeo Therapeutics, Inc. Common Stock's P/E ratio?
Lexeo Therapeutics, Inc. Common Stock's current P/E ratio is -2.7x. This places it at the 50th percentile of its historical range.
What is Lexeo Therapeutics, Inc. Common Stock's ROE?
Lexeo Therapeutics, Inc. Common Stock's return on equity (ROE) is -55.0%. The historical average is -70.2%.
Is LXEO stock overvalued?
Based on historical data, Lexeo Therapeutics, Inc. Common Stock is trading at a P/E of -2.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.